Glioblastoma
Glioblastoma is a fast-growing and aggressive type of brain tumor that arises from glial cells, often leading to severe symptoms and a poor prognosis.
Glioblastoma: Meclofenamate with Temozolomide
We are studying whether adding meclofenamate to standard temozolomide therapy helps patients with progressive MGMT-methylated glioblastoma. The trial will assess safety, effectiveness, and quality of life improvements.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you over 18 years old?
- Are you pregnant or breastfeeding?
- Do you have any major health issues like severe heart disease, liver disease, or active infections like HIV or hepatitis?
- Are you currently taking any medications that are not allowed with this trial, like lithium or methotrexate?
- Have you had any major surgery or treatment for your cancer in the last 3 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Meclofenamate
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Universitaetsklinikum Bonn AöR
Klinik und Poliklinik für Neurologie
Bonn, Germany
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
Klinik und Poliklinik für Neurochirurgie
Dresden, Germany
Universitaetsklinikum Duesseldorf AöR
Klinik für Neurochirurgie
Düsseldorf, Germany
Sponsor: Rheinische Friedrich-Wilhelms-Universitaet Bonn
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.